Wall Street Zen Upgrades Rallybio (NASDAQ:RLYB) to “Buy”

Rallybio (NASDAQ:RLYB) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Rallybio currently has an average rating of “Sell”.

Rallybio Stock Performance

NASDAQ RLYB opened at $16.99 on Friday. Rallybio has a 52-week low of $3.67 and a 52-week high of $17.57. The company has a fifty day moving average of $16.09 and a 200-day moving average of $11.85. The company has a market capitalization of $90.22 million, a P/E ratio of -3.91 and a beta of -0.90.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.28) by $0.19. Rallybio had a negative return on equity of 40.53% and a negative net margin of 911.07%.

Insider Activity at Rallybio

In related news, major shareholder Adar1 Capital Management, Llc bought 10,200 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was purchased at an average price of $13.98 per share, for a total transaction of $142,596.00. Following the acquisition, the insider owned 926,352 shares in the company, valued at $12,950,400.96. This trade represents a 1.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Rallybio

Hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd grew its holdings in Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares in the last quarter. Susquehanna International Group LLP boosted its position in shares of Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares in the last quarter. Geode Capital Management LLC grew its stake in Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares during the last quarter. Citadel Advisors LLC grew its stake in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares during the last quarter. Finally, BlackRock Inc. increased its position in Rallybio by 73.5% during the 2nd quarter. BlackRock Inc. now owns 30,332 shares of the company’s stock valued at $485,000 after buying an additional 12,846 shares in the last quarter. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.